Aug. 11 at 9:50 PM
$MRVI
🚨 🚨 🚨
Base business revenue grew 5% year-over-year, excluding high-volume CleanCap
Biologics Safety Testing segment revenue increased 9.9% to
$16.3 million
Restructuring expected to deliver over
$50 million in annualized cost savings
New license and supply agreement secured with Thermo Fisher Scientific
New leadership team appointed to accelerate innovation and financial performance
Total revenue declined 31.7% year-over-year to
$47.4 million
Net loss of $(69.8) million, including
$30.4 million goodwill impairment
Negative Adjusted EBITDA of $(10.4) million vs positive
$13.0 million in Q2 2024
Nucleic Acid Production revenue decreased 43.1% year-over-year
2025 revenue guidance withdrawn due to business uncertainty
Expected restructuring charges of
$8.0-9.0 million in second half 2025
